Airway disease is on the rise. Asthma is the most common chronic childhood condition, and Chronic Obstructive Pulmonary Disease (COPD), is the fourth leading cause of death in America. Research is underway both to identify risks and to develop therapeutic clinical trials.
HEAL was one of the largest public-private partnerships established to investigate the impact of environmental disparities on human health. Launched in 2006, the program was designed to identify risks associated with developing and exacerbating airway disease, especially asthma, in post-Hurricane Katrina, New Orleans.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that makes it difficult for sufferers to breathe, causing coughing, wheezing, shortness of breath and other symptoms. Affecting as many as 24 million people in the United States, the disease gradually worsens over time and is currently without a cure. Existing treatments can provide only moderate relief of symptoms. Spiromics aims to accelerate the development of new therapies for COPD through the collection and analysis of phenotypic, genetic, proteomic and clinical data from 3,000 individuals with COPD to better identify subpopulations and intermediate outcome measures to help guide more personalized monitoring and therapeutic interventions.